ArticleInflammatory bowel diseases2025
Characterization of Intestinal Mycobiome in Surgical Resections from Inflammatory Bowel Disease Patients: A Deeper Analysis in Complicated Crohn's Disease Phenotypes.
Article in Inflammatory bowel diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Yeasts in the gastrointestinal tract.FEMS yeast research · 2026Review
- Therapeutic potential of ginseng and its bioactive compounds in inflammatory bowel disease: current evidence and future directions.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundInflammatory bowel disease (IBD), which encompasses ulcerative colitis (UC) and Crohn's disease (CD), is a chronic condition characterized by recurrent intestinal inflammation and complications. Despite extensive research on bacterial dysbiosis in IBD, the role of the gut mycobiome remains largely unexplored, particularly in surgical tissue specimens.
methodsIn this study, we performed a comprehensive analysis of the intestinal fungal communities in surgical resections obtained from 20 patients with UC and 30 patients with CD, with non-IBD resections serving as controls. Fungal DNA was extracted and the internal transcribed spacer (ITS) region was amplified and sequenced using high-throughput Illumina technology. RNA from surgical resections from both non-IBD and IBD patients was obtained and the expression of pro-inflammatory and profibrotic genes was analyzed by real-time quantitative polymerase chain reaction.
resultsBioinformatic analysis revealed modest changes in fungal diversity in UC resections compared with those from controls. However, CD specimens exhibited significant alterations in mycobiome composition, including an increased abundance of Malassezia, specifically Malassezia globose, alongside a reduction in Yarrowia lipolytica. Moreover, stratification of CD into complicated phenotypes (B2 stricturing vs B3 penetrating) identified distinct fungal signatures capable of discriminating between these clinical phenotypes. Correlation analyses revealed a direct association between the mycobiome and intestinal inflammation and fibrosis, in parallel with several interactions between fungal and bacterial species, further reporting interkingdom interactions between both microbial communities.
conclusionsThese results underscore the potential of fungal biomarkers in elucidating IBD pathogenesis and its associated complications, which opens up promising avenues for targeted therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.